[go: up one dir, main page]

UY32618A - Combinación antitumoral que comprende ave8062 y sorafenib - Google Patents

Combinación antitumoral que comprende ave8062 y sorafenib

Info

Publication number
UY32618A
UY32618A UY0001032618A UY32618A UY32618A UY 32618 A UY32618 A UY 32618A UY 0001032618 A UY0001032618 A UY 0001032618A UY 32618 A UY32618 A UY 32618A UY 32618 A UY32618 A UY 32618A
Authority
UY
Uruguay
Prior art keywords
ave8062
sorafenib
combination including
antitumoral combination
antitumoral
Prior art date
Application number
UY0001032618A
Other languages
English (en)
Inventor
Vrignaud Patricia
Demers Brigitte
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY32618A publication Critical patent/UY32618A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una combinación farmacéutica antitumoral que comprende AVE8062 de fórmula y sorafenib de fórmula, pudiendo estar estos dos agentes antitumorales en forma de base o en forma de una sal de un ácido farmacéuticamente aceptable.
UY0001032618A 2009-05-07 2010-05-07 Combinación antitumoral que comprende ave8062 y sorafenib UY32618A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
UY32618A true UY32618A (es) 2010-12-31

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032618A UY32618A (es) 2009-05-07 2010-05-07 Combinación antitumoral que comprende ave8062 y sorafenib

Country Status (27)

Country Link
US (1) US20120108641A1 (es)
EP (1) EP2427185A1 (es)
JP (1) JP2012526090A (es)
KR (1) KR20120023754A (es)
CN (1) CN102438608A (es)
AR (1) AR076848A1 (es)
AU (1) AU2010244254A1 (es)
BR (1) BRPI1014197A2 (es)
CA (1) CA2761146A1 (es)
CL (1) CL2011002782A1 (es)
CO (1) CO6390102A2 (es)
CR (1) CR20110573A (es)
DO (1) DOP2011000335A (es)
EA (1) EA201171366A1 (es)
EC (1) ECSP11011440A (es)
FR (1) FR2945210B1 (es)
IL (1) IL216133A0 (es)
MA (1) MA33346B1 (es)
MX (1) MX2011011767A (es)
NI (1) NI201100191A (es)
PE (1) PE20120323A1 (es)
SG (1) SG175895A1 (es)
TN (1) TN2011000551A1 (es)
TW (1) TW201043225A (es)
UY (1) UY32618A (es)
WO (1) WO2010128259A1 (es)
ZA (1) ZA201108110B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481404A1 (en) * 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
PH12012502483A1 (en) * 2010-06-18 2013-03-25 Sanofi Sa An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
WO2015126903A1 (en) * 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
DE69931766T2 (de) * 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
DE60238408D1 (de) * 2001-06-25 2011-01-05 Ajinomoto Kk Antitumorale mittel
CN1318404C (zh) * 2002-02-11 2007-05-30 拜耳制药公司 作为激酶抑制剂的芳基脲类化合物
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
ECSP11011440A (es) 2011-12-30
EP2427185A1 (fr) 2012-03-14
US20120108641A1 (en) 2012-05-03
CO6390102A2 (es) 2012-02-29
JP2012526090A (ja) 2012-10-25
FR2945210A1 (fr) 2010-11-12
EA201171366A1 (ru) 2012-05-30
FR2945210B1 (fr) 2011-07-01
DOP2011000335A (es) 2011-12-15
WO2010128259A1 (fr) 2010-11-11
IL216133A0 (en) 2012-01-31
AU2010244254A1 (en) 2011-11-24
KR20120023754A (ko) 2012-03-13
SG175895A1 (en) 2011-12-29
AR076848A1 (es) 2011-07-13
BRPI1014197A2 (pt) 2016-04-26
MX2011011767A (es) 2012-02-28
CA2761146A1 (fr) 2010-11-11
PE20120323A1 (es) 2012-04-17
NI201100191A (es) 2012-01-16
TW201043225A (en) 2010-12-16
TN2011000551A1 (fr) 2013-05-24
MA33346B1 (fr) 2012-06-01
CN102438608A (zh) 2012-05-02
CR20110573A (es) 2011-12-08
CL2011002782A1 (es) 2012-03-30
ZA201108110B (en) 2013-01-30

Similar Documents

Publication Publication Date Title
CO6390102A2 (es) Combinacion anitumoral que comprende ave8062 y sorafenib
IN2014DN10670A (es)
AR077629A1 (es) Mimetico de smac
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
UA109010C2 (en) Morpholino pyrividines and their use in therapy
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
CO6741228A2 (es) Inhibidores de la neprilisina
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
ECSP11011327A (es) Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia
CY1115852T1 (el) Φαρμακευτικες συνθεσεις
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
ECSP12011585A (es) Compuestos y composiciones para eltratamiento de enfermedades parasitarias
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
PH12012502129A1 (en) New combination therapy in treatment of oncological and fibrotic diseases
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
EA201490199A8 (ru) Терапевтические способы
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
CU20140028A7 (es) Compuesto de benzotiazolona

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140610